DiMarchi to receive award for groundbreaking obesity drug research

Pioneering chemist to receive top honour

Richard DiMarchi, a chemist at Indiana University, will be awarded for his trailblazing research that reshaped obesity treatment. The award recognises his work on drugs that target GLP-1, a hormone that regulates appetite and blood sugar.

DiMarchi's discoveries directly contributed to the development of blockbuster medications such as semaglutide and tirzepatide. These drugs have transformed how doctors approach weight loss and metabolic disease.

From diabetes to obesity: a shift in focus

GLP-1-based therapies were originally designed for type 2 diabetes. DiMarchi and his team realised their potential for obesity treatment early on, pushing the science forward against initial scepticism.

“Obesity was not seen as a disease that could be treated with drugs,” DiMarchi said in a statement. “Our work helped change that perception.” The drugs now help millions lose significant weight and improve metabolic health.

The science behind the breakthrough

GLP-1 mimics a natural hormone that slows digestion and signals fullness to the brain. DiMarchi's lab engineered longer-acting versions, making once-weekly injections possible.

These molecules also showed unexpected benefits for heart health, reducing cardiovascular risks in patients. That dual effect has made them a cornerstone of modern metabolic medicine.

Impact on public health

Obesity affects over 650 million adults worldwide, according to global health estimates. DiMarchi's work offers a pharmacological solution where lifestyle changes alone often fail.

The award comes as demand for these drugs surges, with manufacturers struggling to keep up. Analysts expect the global market for obesity drugs to cross $50 crore by 2030.

What the honour means

Indiana University will present the award at a ceremony later this year. Details of the specific recognition have not been disclosed, but it underscores the university's role in pharmaceutical innovation.

DiMarchi holds over 80 patents and has spent decades bridging academic research and drug development. His work exemplifies how basic chemistry can yield real-world treatments.

What happens next

DiMarchi continues to explore next-generation therapies, including oral versions of GLP-1 drugs and combinations with other hormones. The field is racing to develop cheaper, more accessible alternatives. His award shines a light on Indiana's contribution to a revolution in obesity care.